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This paper describes a population-based study of health care resource use of patients with
chronic obstructive pulmonary disease (COPD) compared to non-COPD controls. Through a
screening of the Danish Patient Registry for patients admitted with COPD diagnoses for a
5-year period, 1998–2002, 66,000 individuals with COPD still alive at the beginning of 2002
were identified. Their use of health care resources in 2002 were compared with equivalent
data, stratified for age, sex and mortality rates, for a control population without COPD
based on data for the 300,000 remaining patients on the Danish Patient Registry in 2002.
Results indicated that the gross cost of treating patients with COPD in the Danish somatic
hospital and primary health care sector corresponded to 10% of the total cost of treating
patients of 40 years or more. The net cost for COPD patients was 1.9 billion DKK (256
million h), 6% of the total annual costs of treating the population of 40 years or more. The
gross cost related to any disease and the net cost reflected the resource use which could be
attributed to COPD and its related diagnoses. The incidence of inpatient hospital
admissions was almost four times higher in the COPD population than in the control group.
COPD patients contacted their general practitioner 12 times more per year than non-COPD
controls, but for specialist and paramedic treatment in the primary care sector there was
no significant difference between COPD patients and non-COPD controls. Only one third of
the COPD costs were due to treatment of COPD as the primary diagnosis. The remainingElsevier Ltd. All rights reserved.
98400; fax: +4535298499.
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L. Bilde et al.540two-thirds of the COPD-related costs were mainly due to admissions for other diseases such
as cardio-vascular diseases, other respiratory diseases, and cancer.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a major
cause of chronic morbidity and mortality throughout the
world. COPD is a disabling, progressive lung disease,
characterised by increasing breathlessness, exacerbations,
immobility and anxiety about suffocation, resulting in slowly
decreasing quality of life over time. The prevalence of COPD
is substantial and increasing. Globally, 9.3 per 1000 men and
6.3 per 1000 women are estimated to have the disease.1 The
disease leads to frequent emergency hospital admissions
due to the exacerbations, and overall, the burden of COPD
on the health care sector is significant and has been
described and documented in previous studies.2–9
The main reason for developing COPD is tobacco smoking,
which in addition to COPD also causes cancer and cardio-
vascular diseases. Because of this and owing to the fact that
the impairment of the lungs has an influence on other vital
organs, co-morbidity is an important feature of a COPD
patient. For example, COPD patients have an increased risk
of right-sided heart failure, coronary heart disease, lung
cancer and other lung diseases, such as pneumonia.10
Although large in number, previous cost-of-illness studies
of COPD are disease- or diagnosis-specific, as they have
considered treatment for COPD only. Since they often fail to
include the co-morbidity aspects, there is a risk that they
have underestimated the real impact of COPD on the use of
health care services. Furthermore, some studies are
bottom-up studies in which resource use is self-reported or
collected from patient records,2,4 a data collection method
which is only practically manageable with a relatively small
sample size. This study provides a supplement to these
studies as it included both co-morbidity aspects of the
disease and involved a total count of patients and their
resource use.
The present study tracked a population of COPD patients
retrospectively for one year and compared this population
with a control group without COPD with regard to the use of
health care resources. Through direct standardisation of the
control group data, using the COPD population as a
reference, the net difference between the two groups was
then calculated. This difference constitutes the real
resource use that can be attributed to COPD and its co-
morbid diagnoses. The method has previously been used to
estimate the cost of treating patients with osteoarthritis in
managed care organisations in the USA.11–14
In an international context, the Danish comprehensive
administrative registers provide ideal possibilities for study-
ing patient populations from register data. Owing to the
existence of a personal identification code, every entry in
the Danish registers on the use of health care services has a
reference to a specific person. Thereby, in principle, the use
of health care resources for each individual person as well as
the entire population can be traced through the registers.
The National Patient Registry contains information abouthospital admissions and discharges, including in-patient and
day case, ambulatory care, and length of stay. In addition,
the register has a recording of diagnoses based on the ICD 10
classification.
The Health Care Reimbursement Scheme Registry con-
tains information on the individual use of primary health
care services, contacts to general practitioners and other
primary care specialists, reimbursement information and
fees. This register does not contain information on diag-
noses. The Register of Medicinal Product Statistics contains
information about the sale of OTC products, individual
purchases of prescribed medicines and reimbursement from
public funds. The Causes of Death Registry has a registration
of all deaths in Denmark and the underlying causes of death.
This register was not yet fully updated for the year studied,
2002. The Register of Medicinal Product Statistics was not
open for register analysis in the year of our study. Our study
focused on data from the two first registers and thus
included the costs related to hospital admissions and
treatment in the primary sector, but not the costs of the
medical treatment outside hospitals.
By use of a number of COPD diagnoses combined with the
personal identification code we studied and compared the
use of health care resources based on data from the National
Patient Registry and the Health Care Reimbursement
Registry, with regard to hospital admissions and primary
care contacts to privately practising health professionals for
the population with COPD and the population without COPD
in 2002.
Methods
Identification of COPD population
The individuals with COPD were identified through a search
in the Danish Patient Registry and included in the COPD
population if they: had at least one case of admission to a hospital with a
COPD diagnosis,15,16 defined as chronic bronchitis without
specification (J42.9), emphysema pulmonum (J43*.*),
other chronic obstructive lung diseases (morbus chron-
icus pulmonum obstructivus alius) (J44*.*) during the
5-year period of 1998–2002. This included both primary
and secondary diagnoses; had at least one contact with the health system in 2002
e.g. hospital admission or primary care consultations; were at least 40 years of age on 1 January 2002.
Furthermore, for each of the identified individuals, the
register was screened 1 year forward from the last contact
in 2002. The individuals who had a contact after the last
contact in 2002 were assumed to be alive and thus included
in the study for the entire year of 2002. In the base case
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2002, the individuals who did not have a contact 1 year after
the last contact in 2002 were only included in 2002 from 1
January to the date of the last contact in 2002 assuming they
were dead. Furthermore, in another scenario, the average
cost and resource use per person year were calculated. In
this scenario, data for these individuals were included 1 year
back from the last contact in 2002. Sensitivity analyses were
conducted to assess the robustness of results, of different
mortality rates in the COPD and control group, and the
impact of controlling for diagnoses not related with COPD. In
the initial screening of the National Patient Registry, ‘‘the
last contact’’ was used as a proxy for mortality, as the
registries were not updated with regard to death dates. Two
years after the initial search in the registries, we validated
this assumption through a new search in the National Patient
Registry for the exact death dates of the COPD individuals
identified. This is covered further in the discussion.
The control group was considered as the Danish popula-
tion aged 40 years or more who did not meet the inclusion
criteria for the COPD population. The control group
accounted for health care resource use in 2002 for app.
2.5 million persons, of whom app. 300,000 were admitted to
hospitals with other diagnoses than COPD. About 2.4 million
individuals (97.4% of the control population) had contacts to
general practitioners and specialists in the primary health
care sector.
The resource use in 2002 was estimated in terms of
hospital bed days, day case admissions, visits to GPs and
primary care specialists, DRG-price per discharge,17 and fee
for consultations and treatment at primary care providers
such as general practitioners, specialists and paramedics.18
The control group means were multiplied by the number
of persons in the different COPD age groups for men and
women, respectively, to calculate the total costs and
resource use in the control group in a direct standardisation
using the COPD population as a reference group.19,20
Results
Population characteristics
Table 1 shows the characteristics of the COPD population
identified during 1998–2002. Of the 66,107 persons with
COPD identified, 53% were women.
A total of 8566 persons or 13% of the population had the
last contact in the registers in 2002 and in the base-case
scenario, their use of health services was included only for
the period up to their last contact.
A total of 34,339 persons or 52% were admitted to hospital
for inpatient treatment at least once during 2002 and 46,205
or 70% had at least one case of hospital ambulatory care. A
total of 11,587 or 18% were admitted to hospital with COPD
as the primary diagnosis, and all, more than 99%, contacted
their GPs and specialists in the primary health care sector in
2002.
Inpatient admissions
Table 2 below shows the mean number of inpatient
admissions, bed-days and length of stay for the twopopulations, COPD and controls in an age-standardised
comparison.
Men with COPD were admitted to inpatient treatment 1.4
times per year, or more than 3 times as often as the control
population without COPD (0.4 times), and women 4 times as
often (1.24 times vs. 0.31 times). This comparison included
patients who were not admitted for inpatient treatment
during the year of study. For patients who were admitted at
least once for in-patient treatment during the year of study,
patients with COPD were on average admitted 2.61 times
(men) and 2.38 times (women) and the equivalent figures for
the inpatients in the control group were lower, that is
1.85–1.68 times for men and women, respectively. The
average number of bed-days attributable to COPD was 7.51
days for men and 7.72 for women, and the average length of
stay was slightly longer for admitted COPD patients than for
admitted patients without COPD, that is 0.52 days longer for
men with COPD, and 0.66 days for women.
Co-morbidity
The COPD patients admitted for inpatient hospital treat-
ment in 2002 accounted for a total of 78,427 admissions. Of
these admissions, only 24.3% were due to COPD as the
primary diagnosis. 13.5% of the admissions were due to
other respiratory diseases (ICD 10 groups J00–J99), 7.3%
to tumours (including cancer ICD 10 groups C00–D48) 16% to
cardiovascular diseases, including ischemic and pulmonary
heart diseases (ICD 10 group I00–I99). Thus, a total of 61% of
the admissions in the COPD population were due to COPD
and related disease groups as the primary diagnosis.
For day case, ambulatory hospital treatment, the picture
was slightly different. Eleven percent of the 261,415
ambulatory visits had COPD as the primary diagnosis and
COPD and related diseases mentioned above constituted
only 35% of the total number of visits.
In Table 3 below, we calculated the incidence per 1000
persons for inpatient hospital admissions with different
primary diagnoses for the COPD population and the popula-
tion without COPD. As expected, the incidence of inpatient
hospital admission with COPD in the control group was 0.
The number of admissions for the COPD population for
almost all diagnoses was at least twice as high as the control
group incidences. In particular, the incidence for admission
with respiratory diseases (J00–J99) was 11 times higher, and
for ischemic heart diseases almost three times higher.
Primary care contacts
Table 4 shows contacts to general practitioners, other
specialists and paramedics in the primary health care sector.
When compared, a difference between the COPD population
and the non-COPD population was seen in the number of
contacts with the general practitioner. These contacts
consisted of consultations at the GP office, emergency visits
to the patient’s home and telephone consultations with the
GP. There were more than 10 GP contacts on average for
men and more than 12 contacts for women attributable to
COPD. For consultations with other specialists, there was no
difference between the groups and thus no COPD attribu-
table resource use.
ARTICLE IN PRESS
Table 1 COPD population, patients admitted in total, patients admitted with COPD as the primary diagnosis, no. of persons
with last contact in 2002.
No. of persons
with COPD (alive
01/01/2002)
No. of persons with
COPD admitted in
2002 (in-patient)
No. of patients in
out-patient hospital
care with COPD
No. of patients with
the primary diagnosis
COPD, 2002
No. of persons
with last
contact in 2002
Men
40–45 years 568 184 367 42 29
45–49 years 1104 380 739 89 49
50–54 years 1650 644 1142 163 111
55–59 years 2856 1210 2023 334 216
60–64 years 3233 1480 2294 463 278
65–69 years 4386 2218 3188 739 475
70–74 years 5688 3082 4214 996 781
75–79 years 5625 3353 4043 1164 961
80–84 years 3863 2422 2571 820 863
85+ years 2331 1508 1351 407 678
Total men 31,304 16,481 21,932 5217 4441
Women
40–45 years 647 221 448 62 17
45–49 years 1293 486 904 125 29
50–54 years 1949 744 1429 247 89
55–59 years 3132 1306 2254 443 161
60–64 years 3710 1684 2727 665 267
65–69 years 5007 2421 3666 1002 476
70–74 years 6132 3298 4397 1308 729
75–79 years 5816 3341 4111 1237 901
80–84 years 4177 2571 2748 836 748
85+ years 2940 1786 1589 445 708
Total women 34,803 17,858 24,273 6370 4125
Women % 53 52 53 55 48
Total COPD 66,107 34,339 46,205 11,587 8,566
Table 2 Number of in-patient admissions, age-standardised means per person year, men and women, 2002.
In-patient admissions 2002
mean figures
Men Women
COPD Controls
(std)
COPD
attributable
COPD Controls
(std.)
COPD
attributable
In-patient admissions per
person in total population
1.40 0.39 1.01 1.24 0.31 0.93
In-patient admissions per
admitted patients
2.61 1.85 2.38 1.68
Beddays per person in total
population
10.28 2.77 7.51 10.15 2.43 7.72
Length of stay (mean per
patient)
7.32 6.80 0.52 8.15 7.49 0.66
The comparison with the control group has deliberately not been undertaken, as these populations are different from the ones
originally compared.
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Table 5 below shows the results of the base-case scenario,
that is, the total cost of treating persons with COPD, the
equivalent costs of treating non-COPD controls, and the net
cost which was attributable to COPD patients in DanishKroner (DKK). ‘‘Costs’’ include public expenses based on
DRG prices and prices used under the health care reimbur-
sement scheme.17,18 Patient co-payments and outpatient
medical expenses in the primary health care sector were not
included. The total COPD cost of 2987 million DKK (401.6
million h, exchange rate from May 2002) amounted to 10% of
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Table 3 Number of in-patient admissions per 1,000 persons in population, per primary diagnosis, 2002.
Comorbidity, incidence of in-patient admissions 2002, COPD and control group No. with primary diagnosis per
1000 persons
Diagnosis groups COPD Control (age-sex-
standardised)
A00–B99: infectious, incl parasitic diseases 23 7
C00–D48: tumours 100 51
D50–D89: diseases in blood and blood producing organs and certain diseases relating to
immune system
20 8
E00–E90: endocrinous and nutrition related diseases and metabolic diseases 28 10
F00–F99: mental and behavioural diseases and disturbances 13 3
G00–G99: diseases in nervous system 14 8
H00–H59: eye diseases 7 4
H60–H95: diseases in ear and processus mastoideus 2 1
I00–I99: cardiovascular diseases excl. I20–I28 133 50
I20–I25: ischaemic heart diseases 73 26
I26–I28: pulmonary heart disease and diseases in lung circuit 5 1
J00–J99: diseases in respiratory organs excl. COPD 177 15
J42–J44 (ekskl. J43.0): COPD 327 0
K00–K93: diseases in digestive organs 82 31
l00–l99: skin and cutaneous diseases 8 3
M00–M99: muscular-skeletal and connective tissue diseases 42 22
N00–N99: diseases in urinary and sex organs 42 21
O00–Q99: pregnancy, delivery, maternity, perinatal diseases, malformations, etc. 1 1
R00–R99: symptoms and abnormal findings not classified elsewhere 67 24
S00–T98: lesions, poisonings and certain other consequences of external exposure 64 31
Z00–Z99: factors of significance for health state, and contacts to health care services 90 30
Table 4 Contacts to general practitioners, other specialists and paramedics in the primary sector, and spirometry
examinations, age-standardised means per person year, men and women, 2002.
No. of contacts, visits and
examinations per person year,
2002
Men Women
Men
COPD
Controls
(std)
COPD
attributable
Women
COPD
Controls
(std.)
COPD
attributable
GP consultations (visits to) 8.1 4.7 3.4 8.3 5.0 3.3
GP telephone consultation 9.3 3.9 5.4 12.2 5.3 6.9
Visit emergency GP 2.4 0.7 1.7 2.8 0.7 2.1
GP consultations total 19.8 9.3 10.5 23.3 11.0 12.3
Spirometry examinations 0.3 0.039 0.261 0.3 0.04 0.26
Consultations at other
specialists etc.
3.5 3.7 0.2 4.7 4.5 0.2
The costs of treating patients with COPD in Denmark 543the total costs of hospital and primary sector care for
patients of 40 years or more in Denmark in 2002. The net
cost of 1927 million DKK (256 million h) amounted to 6% of
the DK total costs. The number of persons accounting for
these costs, app. 66,000, constituted 2.6% of the Danish
population of 40 years of age or more. The main part of
COPD attributable costs was spent on hospital care (97%).
Primary care contacts only accounted for 3% of the
attributable costs.
Table 6 represents the second scenario: the average costs
per person year for COPD and controls and the cost perperson year to be attributed to COPD. Individuals with the
last contact in 2002 were included 1 year back from the last
contact in 2002, so that all individuals accounted for an
entire year.
For the COPD population the median cost per person year
was 22,742 DKK (3058 h), the 75% percentile was 62,082
DKK (8348 h) and the 95% percentile was 196,132 DKK
(26,372 h). For the control population, crude un-standar-
dised figures showed a median of DK 1841 (248 h), 75%
percentile of 6300 DKK (847 h) and a 95% percentile of
55,527 DKK (7466 h).
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Table 6 Average cost per person year for COPD population and non-COPD controls, DKK, 2002.
COPD Controls (age—standardised) Attributable to COPD
Men DKK Women DKK Both sexes, DKK Men DKK Women DKK Both sexes DKK Both sexes DKK
Hospital 49,399 43,911 46,580 16,478 13,143 14,744 31,836
Primary care 3052 3503 3289 2078 2318 2203 1086
Total 52,451 47,414 49,869 18,556 15,461 16,947 32,922
Table 5 Attributable cost of COPD, 2002, DKK.
COPD Controls (age—standardised) Attributable to COPD
Men, DKK Women, DKK Total, DKK Men, DKK Women DKK Total DKK, kr. Total DKK
Hospital 1394 mio. 1.390 mio. 2784 mio. 485 mio. 436 mio. 920 mio. 1863 mio.
Primary care 88 mio. 114 mio. 203 mio. 61 mio. 78 mio. 139 mio. 64 mio.
Total 1482 mio. 1504 mio. 2.987 mio. 546 mio. 513 mio. 1,059 mio. 1.927 mio.
L. Bilde et al.544Robustness, validation and sensitivity analysis
This study was based on a total count of the health care
resource use of all individuals in Denmark of 40 years or
more as their data were entered in the two registers. The
statistical certainty is per se much greater than in studies
based on sampled data. Therefore, results were considered
to be robust.
For the COPD population, we estimated an approximate
date of death from the date of the last contact in the
registers, and for the control group we used general Danish
population data on mortality from Statistics Denmark. The
COPD approximated mortality rate in 2002 was 13%, and the
control group mortality was 4%. The significance of control-
ling for differences in mortality rates for the base-case
scenario resulted in an additional DKK 250 million (33.6
million h) to be attributed to the COPD side, or an increase
in COPD attributable costs of 13%.
In 2005, dates of death in 2002 and 2003 (all causes of
death) were updated in the personal identification register.
A merge between this register and our data file from the
Patient Registry in 2005 provided the exact death dates of
the identified individuals. This dataset showed that 90% of
the individuals with the last contact in 2002 did in fact die in
2002. Although the approximated date of death (the last
contact) is assumed to be premature, as patients do not
always die at hospital or leaving the doctor’s consultation,
our assumption that the last contact to health services can
be used a proxy for death dates of COPD patients was to a
large extent reasonable. Furthermore, despite slight differ-
ences in the definition of the disease, these results were
consistent with another Danish study.21
The other sensitivity analysis excluded costs of treating
diagnoses which were not considered relevant for COPD.
These diagnoses were within the ICD 10 groups H, L, N, O, P,
Q, S and 10, comprising ear, eye and skin diseases, urinary
and venereal diseases, maternity care, lesions and poison-
ing. The significance of excluding these diagnosis groups was140 million DKK (18.8 million h) less on the COPD side
equivalent to a reduction in the attributable costs of
COPD of 7%.Discussion
This study estimated the net resource use of persons with
COPD in Denmark compared with persons without COPD in
2002. The underlying assumption of the study design was
that if COPD has once been diagnosed in a patient, the
patient will have this disease until death. Therefore, had
the patient once been registered with this diagnosis in the
National Patient Register, we could trace the pattern of
health care resource use retrospectively from the inclusion
date until the study ended or the patient died. The main
purpose of this study was to look at the resource use for one
specific year, but there is scope for more research into the
longitudinal patterns of health care resource use for these
patients.
The study’s strengths are the availability of register data
attached to each individual, which were aggregated into
5-year age groups, the total count of individuals, and the
case-control design allowing us to consider co-morbidity
aspects. We found that the cost of managing COPD patients
was almost three times that of managing diseases in the
control group without COPD. Co-morbidity in COPD patients
played a significant role and had great impact on the costs of
treating COPD patients.
Although the gender-related COPD attributable costs
were almost identical, there were more women (53%) than
men in the identified COPD population. This may seem
surprising, as globally, the prevalence of COPD is higher in
men than in women. There may be several reasons for the
excessive number of women in the Danish COPD population.
For many decades, Danish women have had a relatively high
and—until a few years ago—increasing smoking prevalence
compared to women internationally.22 Furthermore, studies
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sensitive to tobacco exposure than men and therefore their
relative risk of developing smoking-related diseases, like
COPD, is higher than that of men.23–25 Our population-based
study supports the findings of these clinical studies.
A limitation of the study is that it only included
individuals who were admitted to hospital with a COPD
diagnosis during the screening period (1998–2002). This
means that a number of persons with COPD, who did not
consult the health care system about their underlying
disease in the screening period, or did so prior to 1998 and
not again since, were not included on the COPD side of the
calculation but on the control side. These individuals were
considered to have COPD in a mild or moderate stage which
did not yet require hospitalisation, and therefore one may
assume that their annual use of the health care system was
only slightly higher compared to the average control group
individual. If this assumption was reasonable it would not
affect the COPD attributable costs, only the number of
persons in each group and the average cost per person year.
Another relevant issue is that of the methods and type of
data chosen. The study relies entirely on the entries and
coding of diagnoses of the administrative data system (the
National Patient Registry). As misclassifications of patients
may occur, there is a risk that some of the COPD ‘‘related
diseases’’ and thus some attributable costs may result from
misclassifications or erroneous coding. However, the choice
of inclusion period, 1998–2002, may have minimized this
risk. Before this period, the coding practices in Denmark
may have been slightly different and going further
back in the registries would have increased the risk of
misclassification.
This study only considered part of the relevant socio-
economic costs of COPD. The cost of medicines, long-term
nursing care, personal assistance and patient co-payments
are examples of direct health costs which were not
included. Furthermore, we did not estimate the present
value of production losses to society resulting from
premature deaths of COPD patients, early retirement and
sick days from work. Had these direct and indirect costs
been included, the estimated impact of COPD on society
would have been much higher. Thus, the cost of COPD
estimated in this analysis is conservative. However, the
exclusion of relevant cost components was made deliber-
ately, to ensure that all data included in the study were
consistent and comparable.
The study used DRG-prices and fees for consultations to
estimate the value of resource use which, theoretically
speaking, do not constitute the real cost of the services.
However, DRG-prices in Denmark are calculated on the basis
of historic costs from hospitals and frequently up-dated, and
only fees for consultation in the primary health care sector
are negotiated prices. As these fees only accounted for 3% of
the total net COPD costs, we consider the analysis more
cost-based than price-based and thus consistent with
theoretical recommendations.
As to the choice of scenarios, we estimated the total costs
of one accounting year (2002) in the baseline scenario, and
adjusted for the excessive (approximated) mortality in the
COPD population in the second scenario, in order to
calculate an average cost per full patient year with COPD.
As people leave the population, others enter the population,and it may be argued that this adjustment is not fully
justified as terminal patients may be over represented.
However, as individuals did not enter the COPD population
until we found them in the register with a COPD diagnosis
related to a hospital admission, and as COPD does not
develop instantly but is slowly progressing, these individuals
were assumed to have had the disease the entire year of
2002 and therefore to have occurred costs on the COPD
population side during the entire year. Thus, in this sense,
they do not replace the individuals who leave the popula-
tion. We tested the significance of this adjustment for
mortality in a sensitivity analysis and found the total COPD-
related costs 13% higher than in the base case scenario.
Cost-of-illness studies show the burden of specific
diseases or as in this case of patients with a certain disease
on health care costs or on society as a whole, but do not
indicate how and with which clinical effect and evidence
these costs are incurred on the system. To include these
aspects, other types of analysis should be applied, e.g. cost-
effectiveness analyses for assessing and comparing different
types of interventions with regard to costs per incremental
effect unit. For these reasons, cost-of-illness analyses may
point to the severity of a problem, but do not provide
the essential information to be used in priority-setting
processes.Conclusion
This paper describes a study on the cost of treating patients
with COPD in the Danish health care sector. An initial
screening of the National Patient Registry identified some
66,000 individuals with diagnosed COPD. Their resource use
in terms of hospital admissions and visits to general
practitioners and other specialists in 2002 were collected
from the National Patient Registry and the Health Care
Reimbursement Scheme Registry and compared with the
equivalent resource use of a control group without COPD.
The COPD population accounted for approximately 10% of
the 2002 health care costs in Denmark related to the
treatment of patients of 40 years or more. The control group
signified the morbidity and resource use of a population
without COPD with the same age and sex composition as the
COPD population. The cost of treating this population was
deducted from the COPD gross cost to calculate the net
costs that could be attributed to the treatment of COPD and
its related diseases. In this comparison, the net cost of
treating patients with COPD in Denmark in 2002 amounted
to approximately 2 billion DKK (256 million h) (6% of total).
Less than one-third of these costs (app. 600 million DKK, (81
million h)) were due to COPD as the primary reason for being
admitted to hospital. COPD might occur as a complicating
diagnosis, or not at all. The majority of the primary
diagnoses (61%) for patients which had once been admitted
to hospital for COPD, were other respiratory diseases,
cardiovascular diseases including pulmonary heart disease
and cancer. The significance of controlling for primary
diagnoses which do not have a causal relationship with
COPD, e.g. lesions and poisonings, was not great. Only 7% of
the COPD attributable costs came from such diagnoses.
Other cost-of-illness studies have only included disease-
specific costs and failed to consider the cost of co-morbidity.
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disease impact on health care resources. This study estimated
the patient-specific costs of COPD in comparison with non-
COPD control and showed the impact of COPD co-morbidity on
health care costs. The study design was inspired by two studies
from the USA on osteoarthritis. Our conclusions were
consistent with their findings: that the cost of treating related
diseases should be included in cost-of-illness estimates.
However, the lack of patient registers, personal identification
codes and access to the data may limit the possibility of
conducting studies like the present in other countries. It is
possible in managed care organisations in the USA, as they are
closed environments data-wise. It is possible on a large scale in
Denmark, as Danish registers count the health care resource
use of more than 5 million people—the entire Danish
population—who are registered with their personal identifica-
tion code from the date of birth to the day they die. It is
expected that a provision will soon be made administratively
for linking information between the National Patient Registry
and the Register for Medicinal Product Statistics. This will
provide another unique possibility for research on diagnosis-
specific prescriptions and sale of medicines in Denmark,
something which will add a valuable contribution to the
estimate of diagnosis-specific resource use.
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